Novel Humanized Anti-HER3 Antibodies: Structural Characterization and Therapeutic Activity.

ABSTRACT:

Background/objectives

The ErbB protein family plays a critical role in the progression of various solid tumors, and HER3 has been implicated in resistance mechanisms to multiple cancer therapies due to its ability to form heterodimers with other ErbB receptors, thereby activating pathways that promote tumor growth and survival. This study aimed to generate and characterize humanized monoclonal antibodies against HER3 to inhibit its function and evaluate their potential as therapeutic agents.

Methods

Murine monoclonal antibodies TK-A3 and TK-A4 were humanized and tested for binding to ErbB3 and competition with neuregulin-1β (NRG). Specificity was assessed by ELISA, and epitope identified by X-ray crystallography. Downstream signaling was analyzed by western blot for phosphor

SUBMITTER: Muzi A 

PROVIDER: S-EPMC12550933 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature